Literature DB >> 28696796

LNG-IUS 12: a 19.5 levonorgestrel-releasing intrauterine system for prevention of pregnancy for up to five years.

Anita L Nelson1.   

Abstract

INTRODUCTION: Globally, intrauterine devices (IUDs) are the second most commonly used form of reversible contraception because of their high efficacy, safety, convenience and cost effectiveness. The levonorgestrel releasing intrauterine system with daily average release of 20 mcg (LNG-IUS 20) is the popular choice because of its favorable bleeding patterns and many noncontraceptive benefits. A three year (LNG-IUS 8) became available three years ago. More recently, the LNG-IUS 12 was added. This new IUD shares a smaller frame, narrow inserter and lower rate of amenorrhea with the LNG-IUS 8, but it offers the five years of contraceptive protection of the LNG-IUS 20. Areas covered: This article provides information on the contraceptive efficacy, safety and tolerability of this new IUS based on approximately 60,000 cycles of use. Where available, the impacts of subject age, parity and body mass index (BMI) on study outcomes are reported. Expert opinion: This new LNG-IUS 12 with mid-dose hormone levels, smaller frame and longer effective life fills a niche that may better meet the needs of women who might appreciate the narrow insertion tube and/or the lower rates of amenorrhea. Cost will ultimately help determine success.

Entities:  

Keywords:  Contraception; Kyleena; LNG-IUS 12; contraceptive efficacy; intrauterine contraception; levonorgestrel; long acting contraception; progestogen contraception

Mesh:

Substances:

Year:  2017        PMID: 28696796     DOI: 10.1080/17425247.2017.1353972

Source DB:  PubMed          Journal:  Expert Opin Drug Deliv        ISSN: 1742-5247            Impact factor:   6.648


  4 in total

1.  Manufacturing and characterization of long-acting levonorgestrel intrauterine systems.

Authors:  Quanying Bao; Bing Gu; Claire F Price; Yuan Zou; Yan Wang; Darby Kozak; Stephanie Choi; Diane J Burgess
Journal:  Int J Pharm       Date:  2018-09-05       Impact factor: 5.875

2.  Adverse events reported for Mirena levonorgestrel-releasing intrauterine device in France and impact of media coverage.

Authors:  Claire Langlade; Amandine Gouverneur; Pauline Bosco-Lévy; Aurore Gouraud; Marie-Christine Pérault-Pochat; Johana Béné; Ghada Miremont-Salamé; Antoine Pariente
Journal:  Br J Clin Pharmacol       Date:  2019-07-31       Impact factor: 4.335

3.  Factors affecting the use of long term and permanent contraceptive methods: a Facebook-focused cross-sectional study.

Authors:  Naser Al-Husban; Dalia Kaadan; Jude Foudeh; Tara Ghazi; Yumen Sijari; Maher Maaita
Journal:  BMC Womens Health       Date:  2022-06-02       Impact factor: 2.742

Review 4.  CE: An Evidence-Based Update on Contraception.

Authors:  Laura E Britton; Amy Alspaugh; Madelyne Z Greene; Monica R McLemore
Journal:  Am J Nurs       Date:  2020-02       Impact factor: 2.577

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.